Horizon2020 Work Programmes for 2018-2020 are published

Horizon 2020 is the biggest EU Research and Innovation programme ever with nearly €80 billion of funding available over 7 years (2014 to 2020) – in addition to the private investment that this money will attract. The new Work Programmes for 2018-2020 are now published.

Horizon 2020 is the financial instrument of the European Commission that aims to drive economic growth and create jobs. Within Horizon 2020, research and innovation are coupled with an emphasis on excellent science, industrial leadership and tackling societal challenges. The goal is to ensure Europe produces world-class science, removes barriers to innovation and makes it easier for the public and private sectors to work together in delivering innovation.

Horizon 2020 is open to everyone

Funding opportunities under Horizon 2020 are set out in multiannual work programmes, which cover the large majority of support available. 

The current main Horizon 2020 work programme comprises an introduction,17 thematic sections and the general annexes describing general rules such as standard admissibility conditions and eligibility criteria, selection and award criteria, etc.

Two of the thematic sections that are specifically relevant for infectious diseases and AMR research are explained below:

Health, demographic change and wellbeing

Building on the principle of openness – open science, open innovation and open to the world the societal challenge on 'health, demographic change and well-being' aims to deliver solutions for a better health for all by:

  • Moving towards the effective integration of personalised medicine approaches into healthcare services and systems to the benefit of patients and citizens;
  • Fighting infectious diseases and the growing threat of antimicrobial resistance;
  • Addressing the needs of the most vulnerable groups and the global increase of chronic diseases;
  • Decoding the role of environment – including climate change and air quality – on health and developing mitigating measures;
  • Exploring the digital potential for health innovation and healthcare, including the building of a 'European health research and innovation cloud';
  • Stimulating innovation in the European healthcare domain and industry by exploring the application of advanced technologies, improve the health of the workforce and promote regulatory science

Within this 'Health' work programme, several topics on infectious diseases are included.

Please contact us when you need support in one of these topics for matchmaking, consortium building and/or proposal writing!

Food security, sustainable agriculture and forestry, marine, maritime and inland water research and the bioeconomy

The Sustainable Food Security call advocates for food system approaches to tackle the inherent links between ecosystems, food production, the food chain and consumer health and wellbeing. The SFS call aims to:

  • deliver diverse and healthy food from land and sea;
  • increase resource efficiency and environmental performance of food systems from primary production to consumers;
  • understand the impact of climate change on agriculture, resources, food quality and identify options to manage its effects;
  • reduce greenhouse gas emissions and emissions of air pollutants from land use and food production taking into account main drivers such as inputs and consumption patterns

Within this 'Food security' work programme, a topic on antimicrobial resistance is included.

Please contact us when you need support in one of these topics for matchmaking, consortium building and/or proposal writing!

  1. More news

  2. BioGeneration Ventures Fund III reaches EUR 82 million in final close

    BioGeneration Ventures (BGV) announces the final closing of its third fund, BGV III at EUR 82 million. Due to strong market interest, the fund has exceeded its original target of EUR 50 million. New investors include biopharmaceutical company Bristol-Myers Squibb, healthcare company Johnson & Johnson Innovation - JJDC, Inc. (JJDC) as well as private equity investor Schroder Adveq, and the MAN Pension Trust. BGV III is now one of the largest funds focused on seed investments in European biotechnology companies.

  3. Unique offer: five-day laboratory training programme at GD Animal Health

    GD Animal Health is more than ready for the future. Seven years of hard work, planning and rebuilding have resulted in an efficient, innovative, sustainable GD Animal Health laboratory with state-of-the-art equipment. The renewed laboratory meets the highest possible quality standards and has been ISO 17025 accredited for a large number of laboratory tests.

  4. TRANSVAC call for vaccine development services is now open!

    TRANSVAC launched a call for vaccine development services on 15 October, 2017.

  5. SGS and Bavarian Nordic to Develop a Novel and Differentiated Challenge Model for RSV

    SGS announced it has entered into collaboration with Bavarian Nordic A/S, an international biotechnology company specializing in vaccines, to develop a new respiratory syncytial virus (RSV) challenge strain.

  6. WHO published report on antibacterial agents in clinical development

    As part of implementation of the Global Action Plan on Antimicrobial Resistance, WHO drew up a list of priority antibiotic-resistant pathogens (priority pathogens list; PPL) to guide research into and the discovery and development of new antibiotics.